One appealing strategy would be to target MAPK activation downstream of RAS: indeed, RAF proteins have been shown to be indispensable for RAS-dependent transformation and progression in several cancer models [36–38]; moreover, early evidence has suggested that the presence of KRAS mutations might portend sensitivity to MEK inhibitors [39–45]. This evidence concerns the gene KRAS and cancer.